secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001628280-24-027399
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics appoints Ron Cooper as Chairman; Glenn Dubin resigns from board
-------------------------------------------------------------------------------

- Ron Cooper appointed Chairman and director effective June 7, 2024, replacing Bruce Downey who remains a board member.
- Director Glenn Dubin resigned effective same date; no disagreements with company.
- Cooper granted stock options for 65,000 shares under 2020 Plan; one-third vests after one year, rest quarterly over two years.
- Cooper brings experience as former CEO of Albireo (acquired by Ipsen) and nearly 30 years at Bristol-Myers Squibb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024027399/0001628280-24-027399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828024027399/cccc-20240610.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-027399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer